|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1399 NEW YORK AVENUE NW |
Address2 | SUITE 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 15920-12
|
||||||||
|
6. House ID# 314640000
|
TYPE OF REPORT | 8. Year | 2014 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Shannon Steward |
Date | 10/15/2014 5:05:38 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
BUD: FY15 Labor, HHS and Education Appropriations related to preparedness for pandemic influenza, HIV/AIDS, hepatitis screening, care and treatment, and access to breast cancer treatment, Issues related to FDA & HHS program funding, FY15 Labor Health and Human Services, and Education, and Related Agencies, H.R. 4800, and FY 15 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills, Following issues related to the budget and appropriations process FY 13 appropriations for FDA as well as the potential outcomes for negotiations on altering sequestration targets via legislation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
Vice President |
|
Eli |
Kogan |
|
Assistant director |
|
Katherine |
Raab |
|
Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Concerns regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program, Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement (Medicare Prescription Drug savings and Choice Act of 2013, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 928/h>r. 1102); issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; HR 4438 - American Research and Competitiveness Act of 2014; Issues related to 340, Medicare coverage and payment of Part B drugs and bilogicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Part B reimbursement; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues. H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and settin forth appropriate budgetary levels for fiscal years 2015 through 2023; and S. Con. Res. 8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 204, revising the appropriate budgetary levles for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023 - Medicare Part B drug reimbursement issues. S.399, American Family Economic Protection Acto f 2013 - sequestration issues affecting Medicare Part B drug reimbursement issues; S. 1871, the SGR Repeal and Medicar Beneficiary Access Act - Medicare physician payment and Part B drug reimburesement issues. H.R. 2810, the Medicare Patient Access and Quality Improvement Act - Medicare physician Payment and Part B drug reimburesement issues
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
Assistant director |
|
Anna |
Griffin |
|
Sr. Director |
|
Katherine |
Raab |
|
Director |
|
Evan |
Morris |
|
Vice President |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies, 340(b) Drug Discount Program, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare presciption drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010- Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - legislation related to reauthorization of user fees for prescription drug, medical device, and biologics approval. All aspects. General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis. S. 959 - Pharmaceutical Quality, Security, and Accountability Act- legislation regarding pharmacy compounding and track and trace proposals. Public Law 113-67, Continuing Appropriations Resolution for 2014 - General public health spending. Public law 113-54- The Drug quality and Security Act - drug compounding and track trace issues.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
Assistant director |
|
Katherine |
Raab |
|
Director |
|
Anna |
Griffin |
|
Sr. Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Intellectual Property and Process Patent Issues - (all provisions), Cyber security, Transpacific partnership
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eli |
Kogan |
|
Assistant director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues relating to biologics, S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act, proposed cuts to Part B reimbursement. 340b reimbursement policy, Issues related to the treatment of biologics in international health programs, Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit.; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
Assistant director |
|
Katherine |
Raab |
|
Director |
|
Evan |
Morris |
|
Vice President |
|
Anna |
Griffin |
|
Sr. Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations, Tax reform, 340 B pricing, research and development tax credit, pandemic preparedness, federal appropriations., Issues related to comprehensive tax reformed the tax treatment of foreign-owned U.S. corporations. S__, Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act (tax extenders), including the R&D tax credit.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eli |
Kogan |
|
Assistant director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |